Canada Newswire -- TORONTO, July 29 /CNW/ - Alexion Pharma Canada, a newly incorporated
division of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), today announced the
availability in Canada of Soliris(TM) (eculizumab) for the treatment of
patients with paroxysmal nocturnal haemoglobinuria (PNH), an ultra-rare,
progressive and life-threatening blood disease characterized by chronic
haemolysis, or red blood cell destruction.
